Table 1.
Features extracted from Pharmaprojects and Trialtrove
| Description | |
|---|---|
| Drug-indication pair | |
| Biological target | protein on which the drug acts |
| Country | country in which the drug is being developed |
| Drug-indication development status | current approval status of the drug-indication pair |
| Indication | indication for which the drug is under development |
| Mechanism of action | mechanism through which the drug produces its pharmacological effect |
| Medium | physical composition of the material in which the drug is contained |
| Name | name of the drug |
| Origin | origin of the active ingredient in the drug |
| Prior approval of drug for another indication | approval of the drug for another indication prior to the indication under consideration |
| Route | route by which the drug is administered |
| Therapeutic class | therapy area for which the drug is in development |
| Trial | |
| Attribute | distinguishing attribute or feature of the trial, e.g., registration trials, biomarkers, immuno-oncology |
| Actual accrual | number of patients enrolled in the trial |
| Disease type | disease, disorder, or syndrome studied in the trial |
| Duration | duration of the trial |
| Exclusion criteria | criteria for excluding a patient from trial consideration |
| Gender | gender of the enrolled patients |
| Investigator experience | primary investigator's success in developing other drugs prior to the drug-indication pair under consideration |
| Location | country in which the trial is conducted |
| Number of identified sites | number of sites where the trial is conducted |
| Outcome | outcome of the trial |
| Patient age | minimum and maximum age of the enrolled patients |
| Patient population | general information about the disease condition of the enrolled patients |
| Patient segment | disease segmentation by patient subtypes, therapeutic objectives, or disease progression/staging |
| Phase 2 end date | year phase 2 ended (end date of the last observed phase 2 trial) |
| Primary endpoint | detailed description of primary objective, endpoint, or outcome of the trial; endpoints are classified into four main groups: efficacy, safety/toxicity, health economics and outcomes research, and pharmacokinetics/pharmacodynamics |
| Sponsor | financial sponsor of the trial |
| Sponsor track record | sponsor's success in developing other drugs prior to the drug-indication pair under consideration |
| Sponsor type | sponsor grouped by type |
| Status | recruitment status of the trial |
| Design | investigative methods used in the trial |
| Design keywords | keywords relating to investigative methods used in the trial |
| Target accrual | number of patients sought for the trial |
| Therapeutic area | therapeutic area of the disease studied in the trial |
See Note S1 for examples of each feature.